Dimeric cinnamoylamide derivatives were synthetized and tested as inhibitors of tyrosinase activity and melanin formation. The most active dimeric cinnamoylamide derivatives was dimeric compound of p-coumaric acid (compound 1) that inhibited tyrosinase activity more efficiently than p-coumaric acid. It also inhibited melanin production by B16 melanoma cell line and normal human melanocytes more efficiently than kojic acid. We next investigated the potential mutagenic and skin sensitization effect of compound 1. Compound 1 was found to induce no mutagenic activity, no irritation and no delayed contact hypersensitivity at the maximum concentration of 10%. In vitro percutaneous absorption studies exhibited that compound 1 could diffuse across the skin till its site of action. All these results lead us to propose that compound 1 may be a safe and effective candidate for treating skin hyperpigmentation related disorders.
Melanocytes are key components of the skin's pigmentary system through their ability to produce melanin. Melanin synthesis or melanogenesis is a complex pathway involving enzymatic and chemical reactions, which in mammals, occur in melanocyte-specific organelles called melanosomes. Among enzymes involved in melanin biosynthesis, tyrosinase is the most critical and rate limiting enzyme that catalyses the first two steps in the biosynthetic pathway: hydroxylation of tyrosine to L-dihydroxyphenylalanine (L-DOPA) and oxidation of L-DOPA to dopaquinone. Pigmented melanosomes are next transferred to contiguous keratinocytes that ultimately ensured the uniform skin color.
Exposure to ultraviolet (UV) radiation increases skin pigmentation and usually results in an even darkening of the skin that in turn constitutes a defense mechanism against UV radiation. However, occasionally a deregulation of melanization can take place locally, such as in melasma, freckles, lentigo senilis, and other forms of melanin hyperpigmentation causing serious aesthetic problems. 1, 2) Thus, tyrosinase inhibitors have become increasingly important in medicinal and cosmetic products for the treatment of these dermatological disorders associated with melanin hyperpigmentation to promote skin whitening or lightening. Whitening cosmetics and medicines such as arbutin, 3) kojic acid 4) and its derivatives have been developed in 1990s but their clinical effect are unsatisfactory. Therefore there is a recognized need for new whitening agents that will be safe and effective.
More recently phenolic compounds such as cinnamic acid and its derivatives (p-coumaric acid, caffeic acid, ferulic acid, isoferulic acid), have been reported to act as tyrosinase inhibitors. [5] [6] [7] [8] It is already accepted that phenolic group-containing molecules can efficiently inhibit tyrosinase activity by interacting with substrate site of enzyme. The presence of hydroxylic groups in position para of phenolic compounds has been suggested as a fundamental requirement for an effective action of these molecules as alternative substrate of tyrosinase. The number and the position of hydroxyl substituents have an important role in determining the activity. 9) These observations prompted us to hypothesize that dimeric molecules containing two phenolic groups could be more efficacious in inhibiting tyrosinase activity compared to monomeric compounds. For this purpose, we have synthetized dimeric cinnamoyl amides ( Fig. 1) derived from the coupling of cinnamic acid derivatives with ethylenediamine by the method described by Hill et al. 10) The aim of the study was to evaluate the effect of these new molecules on tyrosinase activity and melanin biosynthesis.
MATERIALS AND METHODS
Materials L-Tyrosine, mushroom tyrosinase, kojic acid, hydroquinone, synthetic melanin and neutral red solution were purchased from Sigma Chemicals Co. (MO, U.S.A.). Mouse B16 melanoma cells were obtained from ATCC (American Type Culture Collection). Dulbecco's modified Eagle's medium (DMEM) culture medium, gentamycine and fetal bovine serum were from Eurobio (Courtaboeuf, France). Normal human melanocytes and Melanocyte growth medium M2 medium were obtained from Promocell (Heidelberg, Germany).
Chemistry Reactions were monitored by TLC (thinlayer chromatography) using aluminium-coated plates with silica gel 60F 254 (Merck, Germany). H-NMR (nuclear magnetic resonance) spectra were recorded with an AC 50 Bruker AMX 200 MHz spectrometer and 13 C-NMR spectra with a WP-2006-SY Bruker spectrometer. Chemical shifts are relative to tetramethylsilane (TMS) as internal standard. The following procedure described for compound 1 could be used for each derivative.
Synthesis of Compound 1 (Chart 1). 4-Acetoxycoumaric Acid (A)
To a cold solution of coumaric acid 5 g (30.4 mmol) and dimethylaminopyridine (DMAP) (0.09 g, 0.78 mmol) in pyridine (10 ml) was added acetic anhydride (AA) (4.28 ml, 45.6 mmol). The mixture was stirred at room temperature (RT) for 1 h and poured over crushed ice. The solution was acidified (pH Ͻ2) and extracted with ethyle acetate (EtOAc) (3ϫ25 ml). The combined extracts were dried over magnesium sulfate (MgSO 4 4-Acetoxycoumaric Acid Chloride (B) To a stirred solution of 4-acetoxycoumaric acid (3 g, 14.55 mmol) in dry chloroform (CHCl 3 ) (20 ml) containing two drops of dimethylformamide (DMF) was added thionyl chloride (SOCl 2 ) (1.35 ml, 38 mmol). The resulting solution was refluxed for 4 h, allowed to cool and the solvent and excess SOCl 2 removed in vacuo. The acid chloride derivative was used directly in the next step.
Dimeric 4-Acetoxycoumaroyl Amide Derivative (C) To a stirred solution of 1,2-ethylenediamine (0.9 g, 1.5 mmol) and triethylamine (TEA) (0.3 g, 3 mmol) in dry dichloromethane (CH 2 Cl 2 ) (10 ml) was added dropwise a solution of 4-acetoxycoumaric acid chloride (820 mg, 3.7 mmol) in dry CH 2 Cl 2 (10 ml). After the reaction mixture was stirred at 25°C overnight, EtOAc (25 ml) and saturated brine (25 ml) were added. The organic layer was then washed sequentially with 1 M chlorydric acid (HCl) (25 ml), saturated brine (25 ml), 10% sodium hydrogenocarbonate (NaHCO 3 ) (25 ml) and saturated brine (25 ml) and dried over MgSO 4 Dimeric Coumaroyl Amide Derivative (1) A solution of compound C (0.65 g, 1.3 mmol) in acetone (25 ml) was treated at 50°C for 3 h with 3 M HCl. After being cooled, the reaction mixture was diluted with EtOAc (25 ml) and saturated brine (25 ml). The organic phase was dried over MgSO 4 , evaporated under reduced pressure and the crude product recrystallised from methanol. Afforded a white solid, 85%, 0.34 g, mp Ͼ250°C (dec. Mushroom Tyrosinase Assay Tyrosinase activity was determined spectrophotometrically by the modified dopachrome method using L-tyrosine as a substrate.
11) All compounds were first dissolved in dimethyl sulfoxide (DMSO) before being diluted in phosphate-buffered saline (PBS) solution pH 6.8. Mushroom tyrosinase (150 units/ml) was preincubated with PBS, as basal reaction, or with the different compounds in a 96-well microplate at 37°C for 10 min. Then L-tyrosine (0.5 mM) was added and the assay mixture was incubated at 37°C for 15 min. The amount of dopachrome produced in the reaction mixture was measured at 490 nm. Kojic acid and hydroquinone were used as positive standard. The percentage of inhibition of the tyrosinase activity was calculated as follows: tyrosinase inhibition (%)ϭA1/A2ϫ100 where A1 and A2 are absorbance measured in presence or absence of compound respectively. The extent of inhibition by the addition of compound was expressed as the percentage necessary for 50% inhibition (IC 50 ). For each assay IC 50 values were calculated using GraphPad Prism TM software. Cell Culture Mouse B16 melanoma cells were grown in DMEM supplemented with 10% (v/v) fetal bovine serum and gentamycine (0.05 mg/ml), at 37°C in a humidified, CO 2 -controlled (5%) incubator. Normal human melanocytes (NHM) derived from foreskin were cultured in Melanocyte growth medium M2 supplemented with gentamycine (0.05 mg/ml) and all appropriate growth factors and hormones containing-supplement mix. Cells were maintained at 37°C in a humidified, CO 2 -controlled (5%) incubator.
Cell Viability Assay Cell viability was determined using the neutral red uptake method.
12) Cells were left untreated or were exposed to the different compounds. The culture medium was removed and replaced by fresh medium containing the neutral red solution (3.3 g/l). Cells were incubated at 37°C for 4 h. All compounds were dissolved in DMSO and the final concentration of DMSO was 0.1% or below in all experiments. The neutral red retained by viable cells was then extracted with ethanol/acetic acid solution. Absorbance was determined at 540 nm.
Measurement of Melanin Content in NHM and B16 Cells The melanin content was measured using a modification of a previously reported method. 13) Briefly, B16 cells were seeded at 3ϫ10 5 cells/well, cultured for 24 h and next were left untreated or were incubated with the compounds at 0.1 mM (the highest non cytotoxic concentration) in culture medium without red phenol for 3 d. The melanin content was then determined into the medium spectrophotometrically at 490 nm. In normal human melanocytes (NHM), the melanin content was determined by the method of Gordon and Gilchrest 14) with minor modifications. At the end of the treatment, cells were washed with PBS and solubilized in 0.3 ml of 1 N sodium hydroxide (NaOH) for 10 min at 100°C. The absorbance was measured at 490 nm and melanin concentration was extrapolated from a standard curve of known concentrations of synthetic melanin.
Kojic acid was used as positive control. All measurements were carried out in triplicate.
Mutagenicity Assays The following assay was performed as proposed by Ames et al. 15) for each Salmonella typhimurium His Ϫ strains (TA1537, TA1535, TA102, TA100, TA98). Five microliters of the test compound was added to 100 ml of an overnight log-phase bacterial suspension and 95 ml of PBS. Plates were incubated at 37°C under stirring for 90 min. Then, this solution was spread out in a Petri plate containing agar and placed at 37°C. Forty eight hours later, the number of revertant colonies per plate was determined. Sodium azide, 9-amino-acridine, 2-nitrofluorene and mitomycine C were used as positive control for each bacterial strain. All measurements were carried out in triplicate.
The method with metabolic activation was the same as described above, except that PBS was replaced by 95 ml of the S9-fraction. S9 fraction was prepared from rat liver after centrifugation of liver homogenate at 9000 g for 10 min. 2-Anthramine and benzo[a]pyrene were used as positive control for each bacterial strain. All measurements were carried out in triplicate. The statistical significance of the results was assessed with the Dunnett's method.
Skin Sensitization Assays. Animals Nulliparous and non pregnant CBA/J mice (Janvier, Le Genest-Saint-Isle, France) at 8 weeks of age were maintained on a 12 h light/ dark cycle at 20-22°C and acclimated for 5 d before treatment. All animals had free access to SSNIFF R/M-H pellets (SSNIFF Spezialdiäten GmbH, Soest, Germany) and water ad libitum.
Primary Irritancy Assay To establish the minimal irritating and maximal no irritating concentrations of the test compound for use in sensitization experiments and to ensure that the mice would tolerate multiple days of topical exposure to the ear, we conducted a primary irritancy assay following a modification of the method described by Hayes and Meade.
16) The compound 1 was prepared at different concentrations in dimethylformamide (DMF). Twenty-five microliters of the product or of the vehicle (DMF) was applied to the external surface of both ears (one concentration per ear) for 3 consecutive days. Ear thickness was measured with a micrometer on day 1, 2 and 3 (before each cutaneous application) and on day 6. The percent of ear thickness increase between day 1 and day 3 or 6 was calculated.
Local Lymph Node Assay (LLNA) We performed the LLNA according to Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) guidelines and the method described by Kimber et al. 17) The mice (four per treatment group) were treated with the vehicle or with the compound 1 at different concentrations or with 25% ahexylcinnamaldehyde (HCA) used as positive control. On day 6, the animals of all groups were injected intravenously via the tail with 20 mCi of 3 H methyl-thymidine ( 3 H-TdR; Amersham, Les Ulis, France) (specific activity of 25 Ci/ mmol) in 250 ml of NaCl 0.9%. Mice were killed by cervical dislocation and the auricular lymph nodes were excised. The lymph nodes were pooled for each experimental group. Cell suspensions were washed in NaCl 0.9% and their viability was determined by the Trypan blue exclusion test. Each cell suspension was then centrifuged and pellets were precipitated with 5% trichloroacetic acid (TCA) at 4°C overnight. UltimaGold scintillation fluid (Packard Instrument, U.S.A.) was added in order to measure the incorporation of 3 H-TdR using a b-scintillation counter. The results were expressed in disintegrations per minute (dpm) per group. Stimulation Index (SI) was calculated according to the following formula:
SIϭdpm of treated group/dpm of control group
In Vitro Percutaneous Absorption Skin samples were obtained from abdominoplasty surgeries from healthy woman 41 years of age. In vitro skin penetration studies were performed using modified Franz diffusion cells. Diffusion cells were equilibrated in phosphate-buffered saline (pH 7.4) at 37°C for 16 h prior to application of product. Compound 1 was formulated at 0.1%, 0.2% or 0.5% in a cream. An aliquot of each formulation (0.1%, 0.2% and 0.5% of compound 1) was applied onto the skin surface and diffusion cells were incubated at 37°C for 24 h. The amount of compound 1 was assayed by HPLC after tissue extraction. All conditions were done twice in triplicate. The results were analysed by one-way analysis of variance (ANOVA) followed by Fisher test.
RESULTS AND DISCUSSION
First of all, the effect of monomeric and dimeric derivatives (Fig. 2, Table 1 ) was assessed in vitro on tyrosinase activity using purified mushroom tyrosinase. Active compounds were then investigated for their ability to inhibit melanin formation by B16 melanoma cell line. In agreement with our previous observations, 8) 4-hydroxycinnamic acid (pcoumaric acid) (IC 50 ϭ0.2 mM) and 3,4-dihydroxycinnamic acid (caffeic acid) (IC 50 ϭ0.4 mM) exhibited a better efficiency to inhibit tyrosinase activity compared to cinnamic acid (IC 50 Ͼ1 mM) but remained less potent than kojic acid or hydroquinone (IC 50 ϭ0.075 mM and IC 50 ϭ0.037 mM respectively) ( Table 1 ). In addition 3-hydroxy-4-methoxycinnamic acid (isoferulic acid) (IC 50 ϭ0.4 mM) inhibited tyrosinase activity as potently as caffeic acid and p-coumaric acid. On the other hand, its isomer, 4-hydroxy-3-methoxycinnamic acid (ferulic acid), did not inhibit tyrosinase activity corroborating previous results (Table 1) . 7) Interestingly, the dimeric molecule of p-coumaric acid (compound 1) was a potent inhibitor of tyrosinase activity (Table 1) with an IC 50 ϭ0.0057 mM that is 35-and 13 fold lower than the IC 50 of p-coumaric acid and kojic acid respectively. In a same way, dimer of isoferulic acid (compound 3) inhibited tyrosinase activity (IC 50 ϭ0.0085 mM) much more potently than monomeric isoferulic acid. Like its monomer counterpart, dimeric derivatives of ferulic acid (compound 2) did not exhibit inhibition of tyrosinase activity. Noteworthy, substitution of R 1 and R 3 hydroxyls of compound 1 by acetyl moieties (compound 5), abolished the inhibitory potential of compound 1. Similarly, substitution of R 2 and R 4 hydroxyls of compound 3 by acetyl groups (compound 4), blocked the ability of compound 3 to inhibit tyrosinase activity.
Although the presence of hydroxylic groups in position para of phenolic compounds has been suggested by some authors to be important in tyrosinase inhibition, our results provided evidence that it is not so obvious. Indeed our data indicate that the presence of one and/or two hydroxyl groups in phenyl ring, which could compete with L-tyrosine for binding to the active site of the enzyme, might be important in tyrosinase inhibition. 18, 19) Next, we investigated the in vitro inhibitory effect of the different active compounds on melanogenesis. We first performed studies using cultured B16 murine melanoma cells, a cellular model which highly produces and secretes melanin pigment in culture medium. Initially, we performed dose response experiments with all the compounds to assess for their potential cytotoxicity on B16 cells. Even at the highest concentration (0.1 mM), none of these compounds showed a cytotoxic effect (data not shown). Therefore, B16 cells were left untreated or incubated with the different compounds at 0.1 mM, the highest non cytotoxic concentration, and melanin content was determined ( Table 2 ). As shown in Table 2 pcoumaric acid strongly reduced melanin synthesis (54.2%).
In agreement with its effect on tyrosinase activity, compound 1 significantly inhibited melanin synthesis (17%) although less potently than p-coumaric acid but more efficiently than kojic acid that inhibited melanin production at 1 mM.
We could hypothetize that these differences can arise from difference between mushroom and murine tyrosinase amino acid sequence. This discrepancy could also be explained by the weaker acccessibility to the substrate site for dimeric structure in comparison to monomeric molecule. In a same way we could speculate it could be more difficult for dimeric molecule to pass through the cell membrane than monomeric compound.
On the other hand, isoferulic acid and dimeric derivative of isoferulic acid (compound 3) which decreased tyrosinase activity exhibited no inhibitory effect on melanin synthesis. We could hypothetize that either these differences can arise from difference between mushroom and murine tyrosinase amino acid sequence or these two compounds act through a pathway different from the inhibition of tyrosinase activity to prevent melanogenesis (i.e. regulation of melanocytes proliferation).
Then the inhibitory effect of compound 1 on melanogenesis was performed in cultured normal human cells by using NHM which are normal and human melanocytes. NHM were incubated with or without compound 1 at three different non cytotoxic concentrations and intracellular melanin content was determined. As shown in Table 3 , compound 1 inhibited melanin synthesis more efficiently than kojic acid (14% inhibition at 10 mM for compound 1 versus 17.7% inhibition at 300 mM for kojic acid).
Compound 1 was shown to inhibit mushroom tyrosinase activity and prevent melanin synthesis in B16 melanoma cells and in normal human melanocytes. Nevertheless we cannot exclude the possibility that compound 1 could also act at mRNA or protein level to regulate tyrosinase expression and/or act on other membrane or intracellular target involved in melanogenesis regulation.
Thus we decided to go further and to investigate the safety profile of compound 1. For this purpose, we performed a mutagenic assay (Ames test) to detect any potential mutagenic effect of compound 1 using five different Salmonella typhimurium strains. A product is considered as mutagenic when it induces mutation that allows the growth of the histidine auxotrophic strains of Salmonella typhimurium in histidine-free medium. Therefore, the mutagenic effect of compound 1 was investigated in basal condition or in condition that mimicked metabolic activation in order to demonstrate the activity of pro-mutagens and direct mutagens. As shown in Table 4 , compound 1 did not significantly increase the number of revertants in the five bacteria strains after incubation with or without rat liver S9 fraction in contrast to positive control for each bacterial strains that increased the number of revertants. Thus, under the experimental conditions used, compound 1 exhibited no mutagenic activity.
We investigated the skin sensitization potential of compound 1 using primary irritancy assay and local lymph node assay. Mice exposed to 0.5-10% compound 1 experienced no increase in ear swelling relative to vehicle-treated mice (Table 5) . No increase in lymph node cell proliferation was noted at any concentration of compound 1 tested while lymphoproliferation was observed with the known sensitizer ahexylcinnamaldehyde (HCA) (stimulation index Ͼ3). Thus, the compound 1 was found to be non-irritant and did not in- 424 Vol. 34, No. 3 duce delayed contact hypersensitivity at the maximum concentration of 10%.
Finally, we examined skin penetration of compound 1 using in vitro method. Formulations containing different concentrations of compound 1 was applied onto the skin surface. As shown in Fig. 3 , the amount of the compound 1 determined after tissue extraction increased according to the concentration of the product applied onto the surface of the skin. These data indicated that compound 1 could diffuse across cutaneous tissue at up to 0.5% in formulation.
CONCLUSION
It can be concluded from this whole study that dimeric cinnamoyl amide compounds are more efficient to inhibit tyrosinase activity than their monomeric counterparts. Indeed dimeric derivatives of p-coumaric acid (compound 1) and of isoferulic acid (compound 3) inhibit mushroom tyrosinase activity (IC 50 ϭ5.7 mM and IC 50 ϭ8.5 mM respectively) more potently than kojic acid. Evaluated on melanocytes compound 1 can also reduce melanin production (melanoma cell line and normal human melanocytes) more efficiently than kojic acid. Further, our result indicate that the active compound 1 is not mutagenic in vitro and do not induce neither skin sensitisation nor irritation in vivo. Finally, we show that, applied into skin formulated compound 1 can easily diffuse in the epidermis and reach its site of action. All these results lead us to propose that compound 1 may be a potential candidate for treating skin hyperpigmentation related disorders.
